Nasdaq: NTHI−20.91% 24h move
Price before$4.35Aug 11, 2026, 4:00 PM ET
First trade after$5.19Aug 12, 2026, 8:31 AM ET
24h later$3.44Aug 13, 2026, 8:10 AM ET
Complete Announced during: Premarket · announced Wed 8:30a ET (premarket); before = Tue close; first trade Wed 8:31a ET; time = SEC 8-K acceptance
NeOnc Technologies Holdings (Nasdaq: NTHI) reported topline results from a Phase 2 trial of NEO100 in recurrent IDH1-Mutant High-Grade glioma on August 12, 2026. The company said the trial met its primary endpoint.
Trial details
- Drug
- NEO100
- Phase
- Phase 2
- Result
- Met endpointThe study met its primary endpoint.
- Safety
- We look forward to discussing the findings with the FDA.” The data suggests that NEO100 was well tolerated.
- Sponsor
- NeOnc Technologies Holdings Nasdaq: NTHI
- Dates
- Announced Aug 12, 2026, 8:30 AM ET (SEC 8-K filing time)
About this trial
This Phase 2 trial tested NEO100 in Recurrent IDH1-Mutant High-Grade Glioma. NeOnc Technologies Holdings reported that the trial met its primary endpoint.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.